First Pass

5 stories from 4 sources

Fresh capital backs crypto, inference, and healthcare automation

Day’s Recap

Supporting Articles

4:13 PMTechCrunch

AI chipmaker Groq confirms $650M raise, re-staffs after Nvidia’s $20B not-acqui-hire deal

Summary

Groq confirmed a $650 million funding round and is rebuilding its leadership team after a major not-acqui-hire deal in the AI chip market. The company is leaning harder into its hosted inference offering, positioning itself as a neocloud provider rather than only a hardware vendor.

Why it matters

Inference winners will be decided by available capacity and delivery speed, and Groq is using fresh capital to stay in that race even after a talent shock.

8:01 PMFinextra

On-chain trading app fomo raises $75m

Summary

On-chain trading platform fomo raised $75 million in a Series B round led by Index Ventures, with Union Square Ventures and Benchmark also participating.

Why it matters

The round signals renewed institutional conviction in on-chain trading infrastructure and will intensify competition for users, liquidity, and regulatory positioning.

4:25 PMPYMNTS

Fomo Raises $75 Million for Consumer Crypto Trading App

Summary

Fomo raised $75 million in Series B funding for its consumer crypto trading app. The company says the year-old platform has processed more than $4 billion in trading volume and onboarded more than 68,000 first-time crypto traders.

Why it matters

A funded push for retail trading apps can expand crypto adoption fast, but it concentrates risk in the most regulated and most cyclical segment of the market.

12:06 PMPYMNTS

Prosper AI Raises $30 Million to Automate the Patient Journey

Summary

Prosper AI raised $30 million in a Series A led by Andreessen Horowitz to scale its healthcare AI platform. The company sells an end to end workflow that automates patient scheduling, insurance verification, and billing.

Why it matters

A funded push to unify scheduling, verification, and billing raises the bar for healthcare admin software and could accelerate consolidation across the patient access and revenue cycle stack.

Other Developments

A curated list of other prominent stories from this day.

7:00 AMMIT Sloan Management Review

Resolving Muddled Objectives in Corporate Venture Capital

Summary

A cross-company review of 59 highly active corporate venture capital units from 2017 to 2024 finds that many CVC programs run with unclear or conflicting goals, mixing strategic and financial mandates without an operating model to reconcile them. The research compares how major CVCs structure objectives and align investment decisions with parent-company priorities.

Why it matters

Clear CVC objectives change which startups get funded, how fast partnerships form, and whether corporate capital stays durable across strategy cycles.

Make it yours

Build Your First Pass.

Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!